6533b853fe1ef96bd12ad773
RESEARCH PRODUCT
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study
Marina TalamontiMarco GalluzzoAndrea ChiricozziPietro QuaglinoGabriella FabbrociniPaolo GisondiAngelo Valerio MarzanoConcetta PotenzaAndrea ContiAurora ParodiStefano PiasericoFederico BardazziGiuseppe ArgenzianoFranco RongiolettiLuca StingeniGiuseppe MicaliFrancesco LoconsoleMaria Teresa RossiMaria Rita BongiornoClaudio FelicianiPietro RubegniPaolo AmerioMaria Concetta FargnoliPaolo PigattoPaola SavoiaSteven Paul NisticòSandra GiustiniAndrea CarugnoSerafinella Patrizia Cannavo'Giulia RechFrancesca PrignanoAnnamaria OffidaniMaurizio LombardoIris ZalaudekLuca BianchiKetty PerisPso-bio-covid Study GroupBalestri RBernardini NBelloni Fortini ABurlando MCaldarola GCampione ECattaneo ADapavo PDastoli SDe Simone CDi Nuzzo SDiotallevi FFierro MtFranchi CEsposito MFoti CGambini DmGambardella AGirolomoni GGiunta AGuarneri CGualdi GHansel KMegna MMugheddu CMusumeci MlPatrizi APellacani GRichetta AgRosi ESacchelli LTiberio RTilotta GTrovato EVenturini MVezzoni Rsubject
0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusinessdescription
Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-13 |